Latest Content

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Giredestrant improved invasive disease-free survival for people with estrogen receptor-positive early breast cancer compared with standard treatment.

I share how the nurses who cared for my daughter during chemotherapy brought comfort, connection and humanity that carried us through our hardest moments.

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.